Home > News > Starpharma’s VivaGel™ Advance to Third Stage
August 2nd, 2004
Starpharma’s VivaGel™ Advance to Third Stage
Abstract:
Starpharma Holdings Limited announced today that VivaGel™, its investigational new drug for the prevention of HIV, is advancing to the next stage of dosing in the current Phase 1 study. VivaGel™ is the first drug product in the world based upon nanoscale structures called dendrimers, to enter human trials.
Source:
Starpharma
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||